Skip to main content
Fig. 5 | Biology Direct

Fig. 5

From: MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression

Fig. 5

High expression of MAP7D3 predicts poor survival outcomes of triple-negative breast cancer (TNBC) patients and is highly associated with lymph node metastatic tumors and late-stage TNBC. (A) Analysis of the expression of MAP7 family among BC subtypes in TCGA breast cancer dataset using UCSC Xena platform. *P < 0.05. Normal-like, n = 8; Luminal A, n = 231; Luminal B, n = 127; HER2. n = 58; TNBC, n = 98). (B) Collection of the lymph node (LN) metastatic tumors and the primary tumors from the same patient. Quantitative reverse transcription-PCR (qRT-PCR) analysis of MAP7D3 mRNA expression in the LN metastatic tumors and the corresponding primary tumors. *P < 0.05. (C) Analysis of survival outcomes of TNBC patients with or without lymph node metastasis according to MAP7D3 expression was performed using the Kaplan-Meier method in GSE TNBC datasets. Overall survival, relapse-free survival, and distant metastasis-free survival of TNBC patients were estimated based on the best cutoff value of MAP7D3 expression. The survival status was stratified by lymph node positivity of TNBC. (D) Analysis of the correlation between MAP7D3 expression and TNBC stages/grades using Pearson’s Chi-square test. (E) H score of SCEL IHC staining versus TNBC stages. stage I, n = 3; stage II, n = 110; stage III, n = 36. *P < 0.05, ***P < 0.001. (F) H score of SCEL IHC staining versus TNBC grades. grade 1, n = 2; grade 2, n = 82; grade 3, n = 65. ***P < 0.001

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us